• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2023 Financial Results

    3/15/24 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    SHENZHEN, China, March 15, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2023.

    Fourth Quarter 2023 Financial Highlights

    • Net revenues were RMB520.5 million (US$73.3 million) in the fourth quarter of 2023, compared with RMB340.0 million in the same period of 2022.
    • Gross margin was 23.7% in the fourth quarter of 2023, compared with 43.6% in the same period of 2022.
    • U.S. GAAP net income was RMB216.0 million (US$30.4 million) in the fourth quarter of 2023, compared with U.S. GAAP net loss of RMB225.1 million in the same period of 2022.
    • Non-GAAP net income[1] was RMB432.6 million (US$60.9 million) in the fourth quarter of 2023, compared with RMB249.7 million in the same period of 2022.

    Fiscal Year 2023 Financial Highlights

    • Net revenues were RMB1,586.4 million (US$223.4 million) in fiscal year 2023, compared with RMB5,332.8 million in the prior year.
    • Gross margin was 24.4% in fiscal year 2023, compared with 43.2% in the prior year.
    • U.S. GAAP net income was RMB541.0 million (US$76.2 million) in fiscal year 2023, compared with RMB1,408.7 million in the prior year.
    • Non-GAAP net income was RMB903.9 million (US$127.3 million) in fiscal year 2023, compared with RMB1,574.9 million in the prior year.

    "Despite external challenges, we achieved an impressive recovery throughout 2023 through strong strategic execution, setting the stage for new ventures," said Ms. Ying (Kate) Wang, Co-founder, Chairperson of the Board of Directors, and CEO of RLX Technology. "We embarked on our international expansion during the fourth quarter, focusing on markets and product categories with the highest growth potential. By acquiring and integrating resources across diverse markets, we can create powerful synergies and elevate operational efficiency, enhancing our global competitiveness. For our domestic business in China, we remain committed to optimizing our product portfolios while combatting illegal products that still weigh on legitimate players' sales, advocating for a responsible and well-regulated e-vapor industry. Looking ahead, we will continue to expand our business to more markets and develop innovative and premium products to meet our users' evolving needs."

    Mr. Chao Lu, Chief Financial Officer of RLX Technology, commented, "2023 was a pivotal year of progress for RLX's domestic operations. We decisively refined our business structure to align with China's new regulatory environment, driving steady improvements in our financial performance while building a firm foundation for our sustainable future. In the fourth quarter of 2023, we achieved a non-GAAP operating profit of RMB76.1 million, marking a significant turnaround from the previous quarters' losses and reflecting our robust rebound and growth trajectory. Furthermore, we continued to return value to our shareholders through our share repurchase program and cash dividend, with approximately US$112 million in 2023. We also extended our share repurchase program for an additional 24-month period, demonstrating our confidence in the Company's long-term prospects. Going forward, our financial strength and solid balance sheet will empower us to pursue development opportunities that create value for our stakeholders."

    Fourth Quarter 2023 Financial Results

    Net revenues were RMB520.5 million (US$73.3 million) in the fourth quarter of 2023, compared with RMB340.0 million in the same period of 2022. The increase was primarily due to our international expansion in Southeast and North Asia.

    Gross profit was RMB123.4 million (US$17.4 million) in the fourth quarter of 2023, compared with RMB148.3 million in the same period of 2022.

    Gross margin was 23.7% in the fourth quarter of 2023, compared with 43.6% in the same period of 2022. The decrease was primarily due to the imposition of a 36% excise tax, which came into effect on November 1, 2022, and an unfavorable change in revenue mix.

    Operating expenses were RMB263.9 million (US$37.2 million) in the fourth quarter of 2023, compared with RMB620.4 million in the same period of 2022. The decrease was primarily due to a decrease in share-based compensation expenses, which were RMB216.6 million (US$30.5 million) in the fourth quarter of 2023, compared with RMB474.9 million in the same period of 2022. The changes in share-based compensation expenses consisted of (i) RMB12.1 million (US$1.7 million) recognized in selling expenses, (ii) RMB194.2 million (US$27.3 million) recognized in general and administrative expenses, and (iii) RMB10.3 million (US$1.5 million) recognized in research and development expenses. The changes in share-based compensation expenses were primarily due to the changes in the fair value of the share incentive awards that the Company granted to its employees with the fluctuations of the Company's share price.

    Selling expenses were RMB38.0 million (US$5.4 million) in the fourth quarter of 2023, compared with RMB96.7 million in the same period of 2022, primarily due to a decrease in share-based compensation expenses, salaries and welfare benefits.

    General and administrative expenses were RMB204.0 million (US$28.7 million) in the fourth quarter of 2023, compared with RMB394.2 million in the same period of 2022, mainly driven by a decrease in share-based compensation expenses, salaries and welfare benefits.

    Research and development expenses were RMB21.9 million (US$3.1 million) in the fourth quarter of 2023, compared with RMB129.6 million in the same period of 2022, mainly driven by a decrease in share-based compensation expenses, salaries and welfare benefits.

    Loss from operations was RMB140.5 million (US$19.8 million) in the fourth quarter of 2023, compared with RMB472.2 million in the same period of 2022.

    Income tax expense was RMB15.1 million (US$2.1 million) in the fourth quarter of 2023, compared with income tax benefit of RMB16.2 million in the same period of 2022.

    U.S. GAAP net income was RMB216.0 million (US$30.4 million) in the fourth quarter of 2023, compared with U.S. GAAP net loss of RMB225.1 million in the same period of 2022.

    Non-GAAP net income was RMB432.6 million (US$60.9 million) in the fourth quarter of 2023, compared with RMB249.7 million in the same period of 2022.

    U.S. GAAP basic and diluted net income per American depositary share ("ADS") were RMB0.166 (US$0.023) and RMB0.161 (US$0.023) in the fourth quarter of 2023, respectively, compared with U.S. GAAP basic and diluted net loss per ADS of RMB0.174 and RMB0.174, in the same period of 2022.

    Non-GAAP basic and diluted net income per ADS[2] were RMB0.335 (US$0.047) and RMB0.325 (US$0.046), respectively, in the fourth quarter of 2023, compared with non-GAAP basic and diluted net income per ADS of RMB0.188 and RMB0.186, respectively, in the same period of 2022.

    Balance Sheet and Cash Flow

    As of December 31, 2023, the Company had cash and cash equivalents, restricted cash, short-term bank deposits, net, short-term investments, net, long-term bank deposits, net and long-term investment securities, net of RMB15,138.4 million (US$2,132.2 million), compared with RMB15,186.7 million as of September 30, 2023. For the fourth quarter ended December 31, 2023, net cash generated from operating activities was RMB305.2 million (US$43.0 million).

    Fiscal Year 2023 Financial Results

    Net revenues were RMB1,586.4 million (US$223.4 million) in fiscal year 2023, compared with RMB5,332.8 million in the prior year. The decrease was primarily due to the discontinuation of older products.

    Gross profit was RMB387.7 million (US$54.6 million) in fiscal year 2023, compared with RMB2,305.1 million in the prior year.

    Gross margin decreased to 24.4% in fiscal year 2023 from 43.2% in the prior year, primarily due to the imposition of a 36% excise tax, which came into effect on November 1, 2022.

    Operating expenses were RMB884.4 million (US$124.6 million) in fiscal year 2023, representing a decrease of 28.8% from RMB1,241.7 million in the prior year. The decrease in operating expenses was primarily due to the decrease in salaries and welfare benefits.

    Selling expenses decreased by 38.5% to RMB213.7 million (US$30.1 million) in fiscal year 2023 from RMB347.8 million in the prior year, mainly driven by a decrease in salaries and welfare benefits.

    General and administrative expenses decreased by 13.7% to RMB498.0 million (US$70.1 million) in fiscal year 2023 from RMB576.8 million in the prior year, primarily attributable to the decrease in salaries and welfare benefits and accrued liabilities to suppliers.

    Research and development expenses decreased by 45.5% to RMB172.7 million (US$24.3 million) in fiscal year 2023 from RMB317.1 million in the prior year, mainly driven by a decrease in salaries and welfare benefits.

    Loss from operations was RMB496.7 million (US$70.0 million) in fiscal year 2023, compared with an income from operations of RMB1,063.4 million in the prior year.

    Income tax expense was RMB50.8 million (US$7.1 million) in fiscal year 2023, representing a decrease of 86.3% from RMB371.6 million in the prior year.

    U.S. GAAP net income was RMB541.0 million (US$76.2 million) in fiscal year 2023, compared with RMB1,408.7 million in the prior year.

    Non-GAAP net income was RMB903.9 million (US$127.3 million) in fiscal year 2023, compared with RMB1,574.9 million in the prior year.

    U.S. GAAP basic and diluted net income per ADS were RMB0.407 (US$0.057) and RMB0.399 (US$0.056), respectively, in fiscal year 2023, compared with U.S. GAAP basic and diluted net income per ADS of RMB1.092 and RMB1.085, respectively, in the prior year.

    Non-GAAP basic and diluted net income per ADS were RMB0.684 (US$0.096) and RMB0.669 (US$0.094), respectively, in fiscal year 2023, compared with non-GAAP basic and diluted net income per ADS of RMB1.218 and RMB1.210, respectively, in the prior year.

    Share Repurchase Program and Dividend Payment

    The Company repurchased approximately US$98.5 million of its ordinary shares represented by ADSs during the fiscal year of 2023 and US$195.5 million of its ordinary shares represented by ADSs cumulatively, as of December 31, 2023. In December 2023, the Company's board of directors authorized the extension of its existing share repurchase program established in December 2021 for an additional 24-month period through December 31, 2025.

    In November 2023, the Company announced that its Board of Directors approved a cash dividend of US$0.01 per ordinary share, or US$0.01 per ADS, to holders of ordinary shares and holders of ADSs, respectively, as of the close of business on December 1, 2023 Beijing/Hong Kong Time and New York Time, respectively, payable in U.S. dollars. The cash dividend was paid in December 2023 to shareholders. The aggregate amount of the dividend is approximately US$13.0 million.

    Conference Call

    The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 15, 2024 (8:00 PM Beijing/Hong Kong Time on March 15, 2024).

    Dial-in details for the earnings conference call are as follows:

    United States (toll-free):

    +1-888-317-6003

    International:

    +1-412-317-6061

    Hong Kong, China (toll-free):

    +800-963-976

    Hong Kong, China:

    +852-5808-1995

    Mainland China:

    400-120-6115

    Participant Code:

    1473355

    Participants should dial in 10 minutes before the scheduled start time and ask to be connected to the call for "RLX Technology Inc." with the Participant Code as set forth above.

    Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.relxtech.com.

    A replay of the conference call will be accessible approximately two hours after the conclusion of the call until March 22, 2024, by dialing the following telephone numbers:

    United States:

    +1-877-344-7529

    International:

    +1-412-317-0088

    Replay Access Code:

    9792377

    About RLX Technology Inc.

    RLX Technology Inc. (NYSE:RLX) is a leading global branded e-vapor company. The Company leverages its strong in-house technology, product development capabilities, and in-depth insights into adult smokers' needs to develop superior e-vapor products.

    For more information, please visit: http://ir.relxtech.com.

    Non-GAAP Financial Measures

    The Company uses non-GAAP net income and non-GAAP basic and diluted net income per ADS, each a non-GAAP financial measure, in evaluating its operating results and for financial and operational decision-making purposes. Non-GAAP net income represents net income excluding share-based compensation expenses. Non-GAAP basic and diluted net income per ADS is computed using non-GAAP net income attributable to RLX Technology Inc. and the same number of ADSs used in U.S. GAAP basic and diluted net income per ADS calculation.

    The Company presents these non-GAAP financial measures because they are used by the management to evaluate its operating performance and formulate business plans. The Company believes that they help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that are included in net income. The Company also believes that the use of the non-GAAP measures facilitates investors' assessment of its operating performance, as they could provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by the management in its financial and operational decision making.

    The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. They should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per ADS or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review its historical non-GAAP financial measures to the most directly comparable U.S. GAAP measures. The non-GAAP financial measures here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. The Company encourages investors and others to review its financial information in its entirety and not rely on any single financial measure.

    For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliation of GAAP and non-GAAP Results" set forth at the end of this press release.

    Exchange Rate Information

    This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.0999 to US$1.00, the exchange rate on December 29, 2023, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and similar statements. Among other things, quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward- looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; trends and competition in China's e-vapor market; changes in its revenues and certain cost or expense items; PRC governmental policies, laws and regulations relating to the Company's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

    For more information, please contact:

    In China:

    RLX Technology Inc.

    Head of Capital Markets

    Sam Tsang

    Email: [email protected] 

    Piacente Financial Communications

    Jenny Cai

    Tel: +86-10-6508-0677

    Email: [email protected] 

    In the United States:

    Piacente Financial Communications

    Brandi Piacente

    Tel: +1-212-481-2050

    Email: [email protected]

     

    [1] Non-GAAP net income is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    [2] Non-GAAP basic and diluted net income per ADS is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

     

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (All amounts in thousands)











    As of



    December 31,

    December 31,

    December 31,



    2022

    (As adjusted) (a)

    2023

    2023



    RMB

    RMB

    US$

    ASSETS







    Current assets:







    Cash and cash equivalents

    1,268,512

    2,390,298

    336,666

    Restricted cash

    20,574

    29,760

    4,192

    Short-term bank deposits, net

    7,084,879

    2,631,256

    370,605

    Receivables from online payment platforms

    3,000

    6,893

    971

    Short-term investments, net

    2,434,864

    3,093,133

    435,659

    Accounts and notes receivable, net

    51,381

    60,482

    8,519

    Inventories

    130,901

    144,850

    20,402

    Amounts due from related parties

    5,112

    118,736

    16,724

    Prepayments and other current assets, net

    198,932

    508,435

    71,612

    Total current assets

    11,198,155

    8,983,843

    1,265,350

    Non-current assets:







    Property, equipment and leasehold improvement, net

    87,871

    77,358

    10,896

    Intangible assets, net

    7,552

    69,778

    9,828

    Long-term investments, net

    8,000

    8,000

    1,127

    Deferred tax assets, net

    63,894

    58,263

    8,206

    Right-of-use assets, net

    75,008

    52,562

    7,403

    Long-term bank deposits, net

    1,515,428

    1,757,804

    247,582

    Long-term investment securities, net

    3,409,458

    5,236,109

    737,491

    Goodwill

    -

    66,506

    9,367

    Other non-current assets, net

    13,458

    4,874

    686

    Total non-current assets

    5,180,669

    7,331,254

    1,032,586

    Total assets

    16,378,824

    16,315,097

    2,297,936









    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts and notes payable

    269,346

    266,426

    37,525

    Contract liabilities

    75,226

    49,586

    6,984

    Salary and welfare benefits payable

    127,749

    39,256

    5,529

    Taxes payable

    109,676

    77,164

    10,868

    Amounts due to related parties

    423

    101,927

    14,356

    Dividend payable

    -

    881

    124

    Accrued expenses and other current liabilities

    161,455

    103,996

    14,648

    Lease liabilities - current portion

    45,955

    29,435

    4,146

    Total current liabilities

    789,830

    668,671

    94,180









    Non-current liabilities:







    Deferred tax liabilities

    8,653

    23,591

    3,323

    Lease liabilities - non-current portion

    39,968

    24,419

    3,439

    Total non-current liabilities

    48,621

    48,010

    6,762

    Total liabilities

    838,451

    716,681

    100,942

















    Shareholders' Equity:







    Total RLX Technology Inc. shareholders' equity

    15,569,060

    15,609,393

    2,198,540

    Noncontrolling interests

    (28,687)

    (10,977)

    (1,546)

    Total shareholders' equity

    15,540,373

    15,598,416

    2,196,994









    Total liabilities and shareholders' equity

    16,378,824

    16,315,097

    2,297,936



    Note (a): The Company acquired various companies on December 13, 2023, which was accounted for as an under common control transaction in accordance with

    ASC 805-50. The Company retrospectively adjusted the above comparative consolidated balance sheets in prior year.

     

     

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

    COMPREHENSIVE (LOSS)/INCOME

    (All amounts in thousands, except for share and per share data)





















    For the three months ended



    For the year ended



    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,



    2022

    (As adjusted)(b)

    2023

    (As adjusted)(b)

    2023

    2023



    2022

    (As adjusted)(b)

    2023

    2023



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



















      Net revenues

    340,012

    498,929

    520,468

    73,306



    5,332,779

    1,586,397

    223,439

      Cost of revenues

    (139,073)

    (278,578)

    (327,325)

    (46,103)



    (2,974,981)

    (856,329)

    (120,611)

      Excise tax on products

    (52,668)

    (100,313)

    (69,730)

    (9,821)



    (52,668)

    (342,354)

    (48,220)

      Gross profit

    148,271

    120,038

    123,413

    17,382



    2,305,130

    387,714

    54,608



















      Operating expenses:

















      Selling expenses

    (96,673)

    (44,751)

    (37,985)

    (5,350)



    (347,798)

    (213,723)

    (30,102)

      General and administrative expenses

    (394,207)

    (78,849)

    (204,030)

    (28,737)



    (576,811)

    (498,015)

    (70,144)

      Research and development expenses

    (129,558)

    (30,783)

    (21,904)

    (3,085)



    (317,110)

    (172,686)

    (24,322)

      Total operating expenses

    (620,438)

    (154,383)

    (263,919)

    (37,172)



    (1,241,719)

    (884,424)

    (124,568)



















      (Loss)/income from operations

    (472,167)

    (34,345)

    (140,506)

    (19,790)



    1,063,411

    (496,710)

    (69,960)



















      Other income:

















      Interest income, net

    54,617

    158,260

    157,928

    22,244



    180,729

    627,879

    88,435

      Investment income  

    25,557

    21,028

    182,699

    25,733



    136,531

    245,700

    34,606

      Others, net

    150,625

    33,412

    30,925

    4,356



    399,641

    214,874

    30,264

      (Loss)/income before income tax

    (241,368)

    178,355

    231,046

    32,543



    1,780,312

    591,743

    83,345

      Income tax benefit/(expense)  

    16,243

    (1,746)

    (15,078)

    (2,124)



    (371,580)

    (50,755)

    (7,149)

      Net (loss)/income

    (225,125)

    176,609

    215,968

    30,419



    1,408,732

    540,988

    76,196

      Less: net income/(loss) attributable to noncontrolling

    interests

    3,355

    1,579

    2,491

    351



    (32,487)

    6,660

    938

      Net (loss)/income attributable to RLX Technology Inc.

    (228,480)

    175,030

    213,477

    30,068



    1,441,219

    534,328

    75,258

      Other comprehensive (loss)/income:

















      Foreign currency translation adjustments

    (215,246)

    (83,978)

    (132,470)

    (18,658)



    937,428

    198,534

    27,963

      Unrealized (loss)/income on long-term investment securities

    (5,425)

    3,508

    (11,288)

    (1,590)



    (5,425)

    632

    89

      Total other comprehensive (loss)/income

    (220,671)

    (80,470)

    (143,758)

    (20,248)



    932,003

    199,166

    28,052

      Total comprehensive (loss)/income

    (445,796)

    96,139

    72,210

    10,171



    2,340,735

    740,154

    104,248

      Less: total comprehensive income/(loss) attributable to

    noncontrolling interests

    3,355

    1,579

    2,491

    351



    (32,487)

    6,660

    938

      Total comprehensive (loss)/income attributable to RLX

    Technology Inc.

    (449,151)

    94,560

    69,719

    9,820



    2,373,222

    733,494

    103,310



















      Net (loss)/income per ordinary share/ADS 

















       Basic

    (0.174)

    0.133

    0.166

    0.023



    1.092

    0.407

    0.057

       Diluted

    (0.174)

    0.130

    0.161

    0.023



    1.085

    0.399

    0.056



















      Weighted average number of ordinary shares/ADSs

















      Basic

    1,310,229,331

    1,316,452,743

    1,285,752,182

    1,285,752,182



    1,319,732,802

    1,311,401,901

    1,311,401,901

      Diluted

    1,310,229,331

    1,344,359,144

    1,324,466,240

    1,324,466,240



    1,328,144,092

    1,340,445,653

    1,340,445,653



    Note (b): The Company acquired various companies on December 13, 2023, which was accounted for as an under common control transaction in accordance with ASC 805-50. The Company retrospectively adjusted the above

    comparative consolidated statements of comprehensive (loss)/income in prior quarters/year.

     

     

     

    RLX TECHNOLOGY INC.

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

    (All amounts in thousands, except for share and per share data, or otherwise noted)













    For the three months ended



    For the year ended



    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,



    2022

    (As adjusted)(c)

    2023

    (As adjusted)(c)

    2023

    2023



    2022

    (As adjusted)(c)

    2023

    2023



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$

    Net (loss)/income

    (225,125)

    176,609

    215,968

    30,419



    1,408,732

    540,988

    76,196

    Add: share-based compensation expenses

















           Selling expenses

    41,239

    (4,045)

    12,128

    1,708



    (6,993)

    16,700

    2,352

           General and administrative expenses

    369,447

    29,771

    194,153

    27,346



    162,229

    334,344

    47,091

           Research and development expenses

    64,165

    (936)

    10,335

    1,456



    10,925

    11,824

    1,665

    Non-GAAP net income

    249,726

    201,399

    432,584

    60,929



    1,574,893

    903,856

    127,304



















    Net (loss)/income attributable to RLX

       Technology Inc.

    (228,480)

    175,030

    213,477

    30,068



    1,441,219

    534,328

    75,258

    Add: share-based compensation expenses

    474,851

    24,790

    216,616

    30,510



    166,161

    362,868

    51,108

    Non-GAAP net income attributable to RLX

       Technology Inc.

    246,371

    199,820

    430,093

    60,578



    1,607,380

    897,196

    126,366



















    Non-GAAP net income per ordinary share/ADS

















    - Basic

    0.188

    0.152

    0.335

    0.047



    1.218

    0.684

    0.096

    - Diluted

    0.186

    0.149

    0.325

    0.046



    1.210

    0.669

    0.094

    Weighted average number of ordinary

    shares/ADSs

















    - Basic

    1,310,229,331

    1,316,452,743

    1,285,752,182

    1,285,752,182



    1,319,732,802

    1,311,401,901

    1,311,401,901

    - Diluted

    1,324,475,455

    1,344,359,144

    1,324,466,240

    1,324,466,240



    1,328,144,092

    1,340,445,653

    1,340,445,653



    Note (c): The Company acquired various companies on December 13, 2023, which was accounted for as an under common control transaction in accordance with ASC 805-50.The Company retrospectively adjusted 

    the above unaudited reconciliation of GAAP and Non-GAAP results in prior quarters/year.

     

     

     

    RLX TECHNOLOGY INC.



    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



    (All amounts in thousands)

























    For the three months ended



    For the year ended





    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,





    2022

    (As adjusted)(d)

    2023

    (As adjusted)(d)

    2023

    2023



    2022

    (As adjusted)(d)

    2023

    2023





    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



    Net cash (used in)/generated from operating activities

    (248,866)

    82,853

    305,197

    42,986



    486,829

    198,703

    27,987



    Net cash generated from/(used in) investing activities

    752,545

    967,234

    310,274

    43,701



    (4,133,040)

    2,091,145

    294,532



    Net cash used in financing activities

    (150,647)

    (206,577)

    (791,905)

    (111,537)



    (477,270)

    (1,193,216)

    (168,061)



    Effect of foreign exchange rate changes on cash, cash

       equivalents and restricted cash

    29,287

    (5,918)

    (18,544)

    (2,612)



    203,100

    34,340

    4,836



    Net increase/(decrease) in cash and cash equivalents

       and restricted cash

    382,319

    837,592

    (194,978)

    (27,462)



    (3,920,381)

    1,130,972

    159,294



    Cash, cash equivalents and restricted cash at the

       beginning of the period

    906,767

    1,777,444

    2,615,036

    368,320



    5,209,467

    1,289,086

    181,564



    Cash, cash equivalents and restricted cash at the

       end of the period

    1,289,086

    2,615,036

    2,420,058

    340,858



    1,289,086

    2,420,058

    340,858













































    Note (d): The Company acquired various companies on December 13, 2023, which was accounted for as an under common control transaction in accordance with ASC 805-50. The Company retrospectively adjusted

    the above comparative consolidated statements of cash flows in prior quarters/year.



     

     

    Cision View original content:https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-fourth-quarter-and-fiscal-year-2023-financial-results-302090186.html

    SOURCE RLX Technology Inc.

    Get the next $RLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/7/24 6:06:29 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/6/24 4:01:28 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/14/23 6:01:42 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Financials

    Live finance-specific insights

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 14, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on March 14, 2025 - SHENZHEN, China, March 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before the U.S. markets open on Friday, March 14, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 14, 2025 (8:00 PM Beijing/Hong Kong Time on March 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412

      3/3/25 10:30:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    SEC Filings

    See more
    • SEC Form 20-F filed by RLX Technology Inc.

      20-F - RLX Technology Inc. (0001828365) (Filer)

      4/17/25 4:01:47 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      3/14/25 6:10:16 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      11/15/24 4:01:25 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Files 2024 Annual Report on Form 20-F

      SHENZHEN, China, April 17, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC") on April 17, 2025. The annual report on Form 20-F can be accessed on the SEC's website at https://www.sec.gov and on the Company's investor relations website at https://ir.relxtech.com. The Company will provide a hard copy of its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. About RLX Technology Inc. RLX Techno

      4/17/25 8:00:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RLX Technology downgraded by Citigroup with a new price target

      Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

      3/17/25 7:42:34 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • UBS initiated coverage on RLX Technology with a new price target

      UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

      8/8/23 9:12:45 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care